Friday, November 8, 2024 NIAID Researchers Find Anti-HIV Antibodies Affect Immune Responses When Delivered During Acute Infection 3D model of the human Fc receptor. (Credit: NIAID) NIAID scientists examined the effects of modified anti-HIV broadly neutralizing antibodies (bNAbs) that have an increased ability to bind to cells in the body at a region called the Fc receptor. When given during acute—or early—infection in a primate model of HIV, the bNAbs affected innate and adaptive cellular immune responses to the virus. According to the researchers, this could inform future HIV treatment strategies using bNAbs. The study was published in Nature Communications. Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107